De Iuliis Francesca, Salerno Gerardo, Taglieri Ludovica, Lanza Rosina, Cardelli Patrizia, Scarpa Susanna
Experimental Medicine Department, Sapienza University, Rome - Italy.
Clinical and Molecular Medicine Department, Sapienza University, Rome - Italy.
Int J Biol Markers. 2017 Jul 24;32(3):e333-e336. doi: 10.5301/ijbm.5000262.
It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients. Neuregulin-1 (NRG1) and galectin-3 (Gal-3) are proteins that are involved in breast cancer development and patient survival; therefore, we studied whether the serum concentration of these 2 proteins can be correlated to breast cancer progression.
Plasmatic NRG1 and Gal-3 were evaluated in 25 healthy controls and 50 breast cancer patients at baseline and at 3 and 6 months after treatment with anthracyclines and taxanes, with or without trastuzumab.
NRG1 and Gal-3 were significantly more elevated in cancer patients than in healthy controls; furthermore, NRG1 and Gal-3 were significantly increased after chemotherapy and were predictive of mortality at 1 year.
Circulating NRG1 and Gal-3 can be additional biomarkers indicative of prognosis and outcomes for breast cancer patients.
识别有助于评估乳腺癌患者预后和结局的新型血浆生物标志物很重要。神经调节蛋白-1（NRG1）和半乳糖凝集素-3（Gal-3）是参与乳腺癌发展和患者生存的蛋白质；因此，我们研究了这两种蛋白质的血清浓度是否与乳腺癌进展相关。
在25名健康对照者和50名乳腺癌患者中，于基线时以及在使用蒽环类药物和紫杉烷类药物治疗3个月和6个月后（无论是否使用曲妥珠单抗）评估血浆NRG1和Gal-3。
癌症患者的NRG1和Gal-3水平显著高于健康对照者；此外，化疗后NRG1和Gal-3显著升高，且可预测1年死亡率。
循环中的NRG1和Gal-3可作为乳腺癌患者预后和结局的额外生物标志物。
